Skip to main content
. Author manuscript; available in PMC: 2024 May 7.
Published in final edited form as: J Immunol. 2022 Feb 18;208(6):1406–1416. doi: 10.4049/jimmunol.2100900

Figure 5. BCG/αIL-10R1 administration provides long-term protection against M.tb infection.

Figure 5.

IL-10−/− CBA/J mice were vaccinated with saline or BCG (A, C). WT mice were immunized with saline or BCG/αIL-10R1 or BCG/IgG1 (B, D). Mice were infected with M.tb at 7-week post vaccination. Lung and spleen CFU counts in IL-10−/− (A&C) or WT (B&D). Survival curve for IL-10−/− (C) and WT (D) mice. Data in figure 5B are a combined 1 to 3 independent experiments each having 5 mice in each group in all data points. Student’s t test was performed to determine statistical significance between BCG/α-IL-10R1 and BCG/IgG1 (WT) or between saline and BCG (IL-10−/−) immunized experimental groups. *P <0.05; **P<0.01; and P ****P<0.0001. Data in C and D represent a single experiment with 10–14 mice in each group. Log-rank test was used to determine statistical significance of survival between BCG/αIL-10R1 and BCG/IgG1.